Jaguar Animal Health Inc (NASDAQ:JAGX) has received a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.
Brokers have set a 1-year consensus target price of $6.75 for the company and are predicting that the company will post ($0.40) earnings per share for the current quarter, according to Zacks. Zacks has also given Jaguar Animal Health an industry rank of 105 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research downgraded shares of Jaguar Animal Health from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th.
Shares of Jaguar Animal Health (NASDAQ:JAGX) traded down 0.34% during trading on Tuesday, reaching $0.88. 72,902 shares of the company were exchanged. Jaguar Animal Health has a 52-week low of $0.82 and a 52-week high of $4.70. The stock’s market capitalization is $9.79 million. The stock has a 50-day moving average of $1.17 and a 200 day moving average of $1.53.
About Jaguar Animal Health
Jaguar Animal Health, Inc is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jaguar Animal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.